Biotech News

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 17, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future

Open original release

Related news

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

Stock data

Close
32.79 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States